EUVIMEDEUVIMED entdecken
Crossref

Evaluation of Cereblon-Directing Warheads for the Development of Orally Bioavailable PROTACs

Marisa Actis, Joel Cresser-Brown, Elizabeth A Caine iD, Martin Steger, Anup Aggarwal, Anand Mayasundari, Nancy Murphy, Gintvile Valinciute iD, Yong Li, Xiang Fu, Lei Yang, Graham Marsh iD und 13 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c02709 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Marisa Actis und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States. Hauptthemen laut MEDLINE: Ubiquitin-Protein Ligases, Biological Availability. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PROTACs usually occupy physicochemical space outside the one defined by classical drug-like molecules, which often presents considerable challenges in their optimization and development for oral administration. We have previously reported phenyl glutarimide (PG)-based BET PROTAC SJ995973, with improved overall in vitro degradation and antiproliferative activities compared to its direct thalidomide-based analogue dBET1, but similarly poor in vivo pharmacokinetic profile. To further demonstrate the PG utility, we describe here optimization efforts that led to the discovery of an orally bioavailable BET-PROTAC SJ44236 (8), and results of a comprehensive in vitro/vivo comparative study with analogues containing alternative CRBN-directing warheads. Our study highlights the importance of considering warhead modifications when optimizing PROTACs for oral delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin-Protein LigasesBiological AvailabilityHumansAdministration, OralAnimalsMiceAdaptor Proteins, Signal TransducingThalidomideStructure-Activity RelationshipCell Line, TumorRatsAntineoplastic AgentsProteolysis Targeting Chimera

Substanzen

Ubiquitin-Protein LigasesCRBN protein, humanAdaptor Proteins, Signal TransducingThalidomideAntineoplastic AgentsProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
  • Bio-Techne (Tocris), The Watkins Building, Atlantic Road, Avonmouth, Bristol BS11 9QD, U.K.
  • Promega Corporation, 2800 Woods Hollow Rd, Madison, Wisconsin 53711, United States.
  • NEOsphere Biotechnologies GmbH, Fraunhoferstrasse 1, Planegg 82152, Germany.
  • Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.

ORCID-Profile: Elizabeth A Caine, Gintvile Valinciute, Graham Marsh, Martine F Roussel, Hannah Maple, Gisele Nishiguchi, Zoran Rankovic

Zitieren

APA

Actis, M., Cresser-Brown, J., Caine, E. A., Steger, M., Aggarwal, A., Mayasundari, A., Murphy, N., Valinciute, G., Li, Y., Fu, X., Yang, L., Marsh, G., Hughes, G., Karadogan, B., Wheeler, D., Norley, M., Spain, F., Urh, M., Roussel, M. F., …, & Rankovic, Z. (2025). Evaluation of Cereblon-Directing Warheads for the Development of Orally Bioavailable PROTACs. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02709

Vancouver

Actis M, Cresser-Brown J, Caine EA, Steger M, Aggarwal A, Mayasundari A, et al. Evaluation of Cereblon-Directing Warheads for the Development of Orally Bioavailable PROTACs. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02709

BibTeX
@article{Actis2025,
  author = {Actis, Marisa and Cresser-Brown, Joel and Caine, Elizabeth A and Steger, Martin and Aggarwal, Anup and Mayasundari, Anand and Murphy, Nancy and Valinciute, Gintvile and Li, Yong and Fu, Xiang and Yang, Lei and Marsh, Graham and Hughes, Gareth and Karadogan, Burhan and Wheeler, Dean and Norley, Mark and Spain, Freya and Urh, Marjeta and Roussel, Martine F and Schwalb, Björn and Daub, Henrik and Riching, Kristin M and Maple, Hannah and Nishiguchi, Gisele and Rankovic, Zoran},
  title = {Evaluation of Cereblon-Directing Warheads for the Development of Orally Bioavailable PROTACs},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c02709}
}
Kostenlos starten →